ECSP22050936A - Compuestos tric?clicos sustituidos - Google Patents
Compuestos tric?clicos sustituidosInfo
- Publication number
- ECSP22050936A ECSP22050936A ECSENADI202250936A ECDI202250936A ECSP22050936A EC SP22050936 A ECSP22050936 A EC SP22050936A EC SENADI202250936 A ECSENADI202250936 A EC SENADI202250936A EC DI202250936 A ECDI202250936 A EC DI202250936A EC SP22050936 A ECSP22050936 A EC SP22050936A
- Authority
- EC
- Ecuador
- Prior art keywords
- compound
- formula
- tricyclic compounds
- rasopathies
- infectious
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000057028 SOS1 Human genes 0.000 abstract 1
- 108700022176 SOS1 Proteins 0.000 abstract 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 1
- 101150100839 Sos1 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se divulgan compuestos de f?rmula general (I), su forma tautom?rica, su estereois?mero, su sal farmac?uticamente aceptable, su polimorfo o solvato del mismo, en donde, el anillo A, de R1 a R5, X, Y, m, y n son como se definen en el presente documento, para su uso como inhibidores de SOS1 en el tratamiento de enfermedades o trastornos proliferativos infecciosos y rasopat?as. Tambi?n se divulgan m?todos para sintetizar el compuesto de f?rmula I, composiciones farmac?uticas que contienen el compuesto de f?rmula I, un m?todo para el tratamiento de enfermedades o trastornos proliferativos, infecciosos o rasopat?as, por ejemplo, un c?ncer, administrando dicho compuesto y combinaciones del compuesto de f?rmula I con otros principios activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921049157 | 2019-11-29 | ||
| IN202021035414 | 2020-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22050936A true ECSP22050936A (es) | 2022-07-29 |
Family
ID=73856201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202250936A ECSP22050936A (es) | 2019-11-29 | 2022-06-28 | Compuestos tric?clicos sustituidos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230013778A1 (es) |
| EP (1) | EP4065575B1 (es) |
| JP (1) | JP2023504113A (es) |
| KR (1) | KR20220110241A (es) |
| CN (1) | CN114746411B (es) |
| AU (1) | AU2020393205A1 (es) |
| BR (1) | BR112022010383A2 (es) |
| CA (1) | CA3154914A1 (es) |
| CL (1) | CL2022001392A1 (es) |
| CO (1) | CO2022008997A2 (es) |
| CR (1) | CR20220312A (es) |
| DK (1) | DK4065575T3 (es) |
| EC (1) | ECSP22050936A (es) |
| FI (1) | FI4065575T3 (es) |
| HR (1) | HRP20240547T1 (es) |
| IL (1) | IL292721A (es) |
| LT (1) | LT4065575T (es) |
| MX (1) | MX2022006475A (es) |
| PE (1) | PE20221336A1 (es) |
| PL (1) | PL4065575T3 (es) |
| PT (1) | PT4065575T (es) |
| RS (1) | RS65526B1 (es) |
| SI (1) | SI4065575T1 (es) |
| WO (1) | WO2021105960A1 (es) |
| ZA (1) | ZA202206253B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021249475A1 (zh) * | 2020-06-10 | 2021-12-16 | 江苏恒瑞医药股份有限公司 | 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用 |
| AU2021345111A1 (en) | 2020-09-15 | 2023-04-06 | Revolution Medicines, Inc. | Indole derivatives as Ras inhibitors in the treatment of cancer |
| CN117561258A (zh) * | 2021-03-02 | 2024-02-13 | 唯久生物技术(苏州)有限公司 | 作为sos1抑制剂的新型取代的三环氮杂杂环 |
| MX2023011633A (es) | 2021-03-31 | 2023-12-15 | Sevenless Therapeutics Ltd | Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor. |
| TWI807787B (zh) * | 2021-04-19 | 2023-07-01 | 大陸商昆藥集團股份有限公司 | 苯並嘧啶三環衍生物及製備方法和應用 |
| CN115490699A (zh) * | 2021-06-19 | 2022-12-20 | 成都海博为药业有限公司 | 一种稠环化合物及其药物组合物和用途 |
| WO2023287730A1 (en) * | 2021-07-13 | 2023-01-19 | Recurium Ip Holdings, Llc | Tricyclic compounds |
| CN115677699A (zh) * | 2021-07-23 | 2023-02-03 | 武汉誉祥医药科技有限公司 | 三并环化合物及其药物组合物和应用 |
| CN117940411A (zh) * | 2021-08-30 | 2024-04-26 | 浙江海正药业股份有限公司 | 喹唑啉类衍生物、或其制备方法和用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023109929A1 (zh) | 2021-12-17 | 2023-06-22 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的杂环化合物及其用途 |
| WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN116425796A (zh) * | 2022-01-12 | 2023-07-14 | 如东凌达生物医药科技有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
| WO2023135260A1 (en) | 2022-01-14 | 2023-07-20 | Jazz Pharmaceuticals Ireland Limited | Novel amine-substituted phthalazines and derivatives as sos1 inhibitors |
| WO2023138691A1 (en) * | 2022-01-21 | 2023-07-27 | Shenzhen Ionova Life Science Co., Ltd. | Fused heterocyclic compounds as modulators of ras signalling |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| GB202203976D0 (en) | 2022-03-22 | 2022-05-04 | Jazz Pharmaceuticals Ireland Ltd | Tricyclic phthalazines and derivatives as sos1 inhibitors |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2004003152A2 (en) | 2002-06-26 | 2004-01-08 | Chiron Corporation | Sos1 inhibitors |
| US20070065622A1 (en) | 2005-09-22 | 2007-03-22 | Scientific Technologies Incorporated | Safety Mat Active Joining Trim |
| GEP20146125B (en) | 2009-12-17 | 2014-07-25 | Merck Canada | Aminopyrimidines as syk inhibitors |
| US10087215B2 (en) * | 2013-03-15 | 2018-10-02 | Dana-Farber Cancer Institute, Inc. | Stabilized SOS1 peptides |
| WO2016077793A1 (en) | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| CN109071560B (zh) | 2016-02-12 | 2022-01-14 | 瓦洛健康公司 | 用作泛素特异性蛋白酶抑制剂的噻吩并吡啶甲酰胺 |
| WO2018115380A1 (en) | 2016-12-22 | 2018-06-28 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| WO2018172250A1 (en) * | 2017-03-21 | 2018-09-27 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| US10829487B2 (en) | 2017-12-21 | 2020-11-10 | Boehringer Ingelheim International Gmbh | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors |
| US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
-
2020
- 2020-11-28 AU AU2020393205A patent/AU2020393205A1/en active Pending
- 2020-11-28 DK DK20828308.5T patent/DK4065575T3/da active
- 2020-11-28 CA CA3154914A patent/CA3154914A1/en active Pending
- 2020-11-28 LT LTEPPCT/IB2020/061248T patent/LT4065575T/lt unknown
- 2020-11-28 JP JP2022531526A patent/JP2023504113A/ja active Pending
- 2020-11-28 PT PT208283085T patent/PT4065575T/pt unknown
- 2020-11-28 KR KR1020227022095A patent/KR20220110241A/ko unknown
- 2020-11-28 CN CN202080083011.4A patent/CN114746411B/zh active Active
- 2020-11-28 BR BR112022010383A patent/BR112022010383A2/pt unknown
- 2020-11-28 FI FIEP20828308.5T patent/FI4065575T3/fi active
- 2020-11-28 SI SI202030421T patent/SI4065575T1/sl unknown
- 2020-11-28 RS RS20240468A patent/RS65526B1/sr unknown
- 2020-11-28 HR HRP20240547TT patent/HRP20240547T1/hr unknown
- 2020-11-28 CR CR20220312A patent/CR20220312A/es unknown
- 2020-11-28 WO PCT/IB2020/061248 patent/WO2021105960A1/en active Application Filing
- 2020-11-28 US US17/775,679 patent/US20230013778A1/en active Pending
- 2020-11-28 MX MX2022006475A patent/MX2022006475A/es unknown
- 2020-11-28 PL PL20828308.5T patent/PL4065575T3/pl unknown
- 2020-11-28 PE PE2022000814A patent/PE20221336A1/es unknown
- 2020-11-28 EP EP20828308.5A patent/EP4065575B1/en active Active
-
2022
- 2022-05-03 IL IL292721A patent/IL292721A/en unknown
- 2022-05-27 CL CL2022001392A patent/CL2022001392A1/es unknown
- 2022-06-06 ZA ZA2022/06253A patent/ZA202206253B/en unknown
- 2022-06-28 CO CONC2022/0008997A patent/CO2022008997A2/es unknown
- 2022-06-28 EC ECSENADI202250936A patent/ECSP22050936A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4065575T3 (da) | 2024-04-15 |
| LT4065575T (lt) | 2024-05-27 |
| BR112022010383A2 (pt) | 2022-08-23 |
| CO2022008997A2 (es) | 2022-07-19 |
| ZA202206253B (en) | 2023-01-25 |
| AU2020393205A1 (en) | 2022-06-30 |
| CN114746411B (zh) | 2024-06-25 |
| KR20220110241A (ko) | 2022-08-05 |
| HRP20240547T1 (hr) | 2024-07-05 |
| EP4065575B1 (en) | 2024-01-31 |
| PE20221336A1 (es) | 2022-09-13 |
| SI4065575T1 (sl) | 2024-06-28 |
| MX2022006475A (es) | 2022-09-07 |
| CL2022001392A1 (es) | 2023-03-17 |
| PL4065575T3 (pl) | 2024-06-24 |
| CA3154914A1 (en) | 2021-06-03 |
| EP4065575A1 (en) | 2022-10-05 |
| CN114746411A (zh) | 2022-07-12 |
| WO2021105960A1 (en) | 2021-06-03 |
| PT4065575T (pt) | 2024-05-03 |
| JP2023504113A (ja) | 2023-02-01 |
| US20230013778A1 (en) | 2023-01-19 |
| FI4065575T3 (fi) | 2024-05-02 |
| CR20220312A (es) | 2022-08-05 |
| RS65526B1 (sr) | 2024-06-28 |
| IL292721A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22050936A (es) | Compuestos tric?clicos sustituidos | |
| ECSP22058816A (es) | Compuestos tric?clicos sustituidos | |
| PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| ECSP22046699A (es) | Inhibidores de kras g12c | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| BR112021024131A2 (pt) | Derivado de anel inibidor de btk, método de preparação para o mesmo e aplicação farmacêutica do mesmo | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| PE20200341A1 (es) | Composiciones y compuestos terapeuticos y metodos para utilizarlos | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CU24543B1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| ECSP18056196A (es) | Derivados de indano | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 |